Significant racial disparity remains in the incidence of unfavorable outcomes following heart transplantation. We sought to determine which pediatric posttransplantation outcomes differ by race and whether these can be explained by recipient demographic, clinical, and genetic attributes. Data were collected for 80 black and 450 nonblack pediatric recipients transplanted at 1 of 6 centers between 1993 and 2008. Genotyping was performed for 20 candidate genes. Average follow-up was 6.25 years. Unadjusted 5-year rates for death (p = 0.001), graft loss (p = 0.015), acute rejection with severe hemodynamic compromise (p = 0.001), late rejection (p = 0.005), and late rejection with hemodynamic compromise (p = 0.004) were significantly higher among blacks compared with nonblacks. Black recipients were more likely to be older at the time of transplantation (p < 0.001), suffer from cardiomyopathy (p = 0.004), and have public insurance (p < 0.001), and were less likely to undergo induction therapy (p = 0.0039). In multivariate regression models adjusting for age, sex, cardiac diagnosis, insurance status, and genetic variations, black race remained a significant risk factor for all the above outcomes. These clinical and genetic variables explained only 8-19% of the excess risk observed for black recipients. We have confirmed racial differences in survival, graft loss, and several rejection outcomes following heart transplantation in children, which could not be fully explained by differences in recipient attributes.
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Introduction
Transplantation is a therapeutic option offering the possibility for long-term survival and improved quality of life for many infants and children with severe cardiac disease. Advances over the last three decades, including in immunosuppressive therapy, have contributed to improved outcomes. Nevertheless, significant racial disparity remains, particularly for long-term outcomes (1, 2) . Black race has been consistently associated with a number of adverse posttransplantation outcomes (3) (4) (5) (6) . Several studies have examined the impact of differences in socioeconomic status (SES) and access to care by race as a means to explain these disparities and have concluded that these factors alone are not the sole cause (7) (8) (9) . Genetic variation has been hypothesized to play a role in predisposition to certain posttransplant outcomes
Detection of genetic polymorphisms
A total of 33 allelic variations were examined for 20 genes involved in the immune response to an allograft or involved in the transport and metabolism of immunosuppressive medications (Table S1) . A 3-6-mL anticoagulated peripheral venous blood sample was collected from each participant after study enrollment. QIAamp DNA Blood Midi Kit and REPLI-g Mini/Midi Kit (Qiagen Inc, Alameda, CA) were used for genomic DNA extraction and amplification, respectively. Samples were then stored for future batched analysis. Gene variants were identified as previously described (13, 18) .
Data collection and clinical outcomes
Demographic and clinical data were obtained from the PHTS database. At study entry, the racial/ethnic background for each patient was recorded based on parent-described responses. For the purposes of our study, racial categories were defined as either black or nonblack, and ethnicity as either Hispanic or non-Hispanic. Initial immunosuppressive regimens and drug use at annual follow-up were recorded. Immunosuppressive regimens were determined by site clinical standard of care. Clinical outcomes were captured prospectively on standardized case report forms at each clinical site and entered into the PHTS database. Methods of data collection, verification, and entry for the PHTS have been described elsewhere (17) . The outcomes of interest for our study included: acute rejection, infection, posttransplantation lymphoproliferative disease (PTLD), cardiac allograft vasculopathy (CAV), graft loss, and death. Rejection is defined by PHTS as an event (biopsy or other criteria) leading to acute augmentation of immunosuppressive therapy (16, 17) . Acute rejection was classified as late when occurring beyond the first year posttransplantation (19, 20) and as associated with rejection with hemodynamic compromise (RHC) when there was concomitant evidence of deteriorating cardiac function and/or heart failure (21, 22) . RHC was considered severe when inotropic support was initiated (21, 22) . Infections within the PHTS are only collected when deemed serious, defined as requiring hospital admission and/or parenteral antimicrobial therapy. All serious infections were classified as bacterial, fungal, viral, or of unknown etiology.
Statistical analyses
Baseline demographic, clinical, and genetic characteristics were compared between racial groups and are presented as counts and percentages with chi-square statistics. Recipient-donor mismatches and initial drug therapy following transplantation were also analyzed by race. Genetic variables were coded based on the additive assumption, and we systematically examined the association between each genetic variable and each specified clinical outcome using unadjusted Cox regression models. Kaplan-Meier methods and log rank statistics were used to estimate and compare the cumulative clinical event rates by race, and Cox proportional hazards regression models were created to compare these outcomes adjusting for baseline demographic, clinical, and genetic factors. For each clinical outcome, a series of hierarchical multivariable Cox regression models were created to evaluate the effect of race as follows:
(1) unadjusted model of the association between race and clinical outcome; (2) model adjusting for recipient age at time of transplantation, sex, transplantation etiology (defined as cardiomyopathy [yes/no]) and health insurance type (defined as public insurance [yes/no]); and (3) model adjusting for demographic and clinical factors, and gene polymorphisms. Gene polymorphisms associated with each clinical outcome were identified using forward stepwise regression selection methods (p-value for entry p < 0.10). The interaction between race and each identified gene polymorphism was tested by adding the cross-product term to the corresponding model and considering its statistical significance. Adjusted hazard ratios (HR) and 95% confidence intervals (CI) are reported. The percent of the excess race-risk explained by clinical and genetic factors was computed as (HR unadjusted ÀHR adjusted )/ (HR unadjusted À1). All statistical tests are two-sided and p-value ≤0.05 was used to define statistical significance. All analyses were performed using SAS 9.2 software (SAS Institute, Cary, NC).
Results

Baseline characteristics
Five hundred thirty patients transplanted between January 1993 and December 2008 and followed within the PHTS were consented and enrolled in the present study. Of these, 80 (15.1%) were reported as black race and the remaining 450 (84.9%) as nonblack. The majority of the black population was of non-Hispanic ethnicity (67, 83.8%). The nonblack cohort comprised 318 (70.7%) white non-Hispanic patients, 98 (21.8%) Hispanic patients, and 34 (7.5%) patients who were described as "Other" non-Hispanic.
The baseline demographic and clinical characteristics are summarized in Table 1 . The median age at time of transplant was 3.8 years. Black patients were significantly older at the time of transplantation; 10 (12.5%) black patients and 157 (35%) nonblack patients were less than 1 year of age when transplanted (p < 0.001). The majority of black patients had cardiomyopathy (53, 66.3%), while the diagnoses of congenital heart disease (220, 48.9%) and cardiomyopathy (205, 45.6%) were more evenly distributed among nonblack patients. Patients of black race were more likely to have public health insurance as compared to nonblack patients (57.5% vs. 28.9%, p < 0.001). The enrolling transplant center was strongly associated with race (p < 0.001). Although 46% of the black recipients came from one center, all six centers each contributed greater than five patients of black race and of nonblack race.
Single nucleotide polymorphism frequencies of genes encoding cytokines, growth factors, effector molecules, and genes involved in drug disposition were compared by race (Table 2 ). Variant distribution was significantly different (p < 0.05) by race for 22 of the 33 genotyped variants. The observed genotype frequencies did not deviate from Hardy-Weinberg equilibrium for the total cohort.
The proportion of gender, race, and cytomegalovirus (CMV) status mismatches between recipients and donors by race is summarized in Table 3 . Black recipients were more likely to receive an organ from a donor of different race compared to nonblack recipients (75% vs. 34.7%, p < 0.001). HLA data were available for 318 (60%) patients in the study cohort (nonblack, n = 274; black, n = 44). The percentage of HLA mismatches was not significantly different (Table 4) .
Immunosuppressive regimens
The immunosuppressive regimens at the time of hospital discharge and at subsequent years over follow-up are presented by race in Table 5 . In this cohort, use of azathioprine was slightly higher among those with public as compared to those with private insurance (48.3% vs. 43.6%, p = 0.344), and induction therapy was more common among those with public as compared to private insurance (60.2% vs. 45.3%, p = 0.003). Of the 530 patients in the study, 271 (51.1%) underwent induction therapy with a significantly higher proportion of nonblack patients receiving induction therapy (53.8% vs. 36.3%, p = 0.0039). At the time of initial hospital discharge nearly the entire study cohort (518, 97.7%) received maintenance corticosteroids. The number of patients receiving corticosteroids as part of their immunosuppressive regimen decreased with each passing year; however, the proportion of black patients receiving corticosteroids was significantly higher than that of nonblack patients out to year 4 of posttransplant follow-up (32.4% vs. 17.6%, p = 0.0420).
Posttransplantation outcomes
The average time of follow-up for the cohort and for the transplanted heart was 6.25 (SD AE 3.19) years and 6.11 (SD AE 3.17) years, respectively. Of the 530 pediatric Posttransplantation outcome rates by race and ethnicity Kaplan-Meier estimates of mortality and rejection rates by race over 8 years posttransplantation are presented in Figure 1 . Unadjusted 5-year rates for death, graft loss, RHC requiring inotropes, late rejection, and late RHC were significantly higher among black compared with nonblack patients (Figure 2 ). Genotypes and allele frequencies did not deviate from Hardy-Weinberg equilibrium in the total cohort. There were no significant differences observed by race for time to first rejection, recurrent rejection, number of rejection episodes, time to first infection, types or numbers of infections, PTLD, or CAV. No significant differences were found between Hispanic and non-Hispanic white populations for any of the outcomes analyzed.
Contribution of clinical and genetic factors to posttransplant outcomes
In univariate unadjusted models, the influence of common genetic variations on each outcome of interest is reported for associations with p-value <0.1 (Table 6 ).
For each of the five outcomes for which unadjusted event rates differed by race, a multivariable model was constructed to determine the influence of race adjusting for demographic, clinical, and genetic contributions. The findings of these final multivariable models are shown in Table 7 .
Of note, black race was an independent predictor of the risk of death (HR = 3.29, 95% CI 1.44, 7.50, p = 0.0047) adjusting for demographic, clinical, and genetic variants in ACE (number of D alleles HR = 3.03, p = 0.0004) and TNFa (G alleles HR = 2.91, p = 0.076). Similarly, for time to graft loss, black race was a significant independent predictor (HR = 2.05, 95% CI 1.02-4.10, p = 0.044) as were genetic variants in ACE (number of D alleles HR = 1.90, p = 0.0037) and IFNc (A alleles HR = 1.59, p = 0.045). None of the interactions between race and the identified gene polymorphisms were significant, and hence the cross-product terms were not included in any of the final models.
The demographic, clinical, and genetic factors explained approximately 8% of the observed excess risk for black We also tested the effect of transplant center on the five clinical outcomes reported in Table 7 . Although transplant center was associated with some of the rejection outcomes (specifically RHC requiring inotropes, p = 0.017; and late rejection, p = 0.001), it was impossible to adjust for center along with the other relevant demographic variables (which may explain part of the center effect) given the low number of events. 
Discussion
Despite advancements over the last few decades in the field of transplantation, there remains a prominent racial disparity in recipient outcomes. Several studies have shown a negative impact of black race on survival after transplantation (23) (24) (25) (26) . This observation is of great concern to patients, families, healthcare providers, policy makers, and society at large (27) . The primary goal of this study was to attempt to understand these differences more clearly and to search for explanations for such disparities. This is the first study to examine the influence of race as an independent predictor of multiple clinical outcomes in a large cohort of pediatric heart transplant recipients taking into account demographic, clinical, and genetic variables.
Do racial disparities exist for clinical outcomes after pediatric heart transplantation?
We observed that death was significantly more common among black recipients. Estimated rate of death at 5 years was almost three times higher among blacks and graft loss was observed almost two times as often among blacks. Although power was limited in this study, we did not observe such differences by Hispanic ethnicity. Of note, the racial differences in mortality and graft loss did not become evident until several years after transplantation. These observations are similar to those observed by others (2, 3) . This may, in part, reflect overlapping study populations. However, these observations are also consistent with findings among adult heart transplant recipients (26, 28, 29) and other pediatric transplant populations (30) (31) (32) (33) , emphasizing that this is a broad phenomenon not specific to pediatric heart transplantation or to any one age group.
Transplantation registries often have limited outcome data beyond graft and patient survival. Therefore, the relationship of other transplant outcomes to race and ethnicity has been less well studied. In the current study, we observed other unfavorable clinical outcomes when comparing black to nonblack recipients, mostly related to rejection events. In our unadjusted models, severe RHC, late rejection, and late RHC were observed in a greater proportion of black recipients. These observations are highly relevant since these are outcomes associated with high risk of mortality (21, 34) . Of note, time to first rejection did not differ between racial groups, and this outcome is known not to have a strong relation to late outcomes of death or graft loss (19) . RHC and freedom from recurrent rejection approached significance in the unadjusted models and both have previously been associated with adverse patient and graft outcomes (22) . Overall, all these observations are consistent with prior studies in the pediatric population (20) .
We did not observe significant differences in outcomes by race for infections, PTLD, or CAV. Few studies are available for comparison, though Dharnidharka and colleagues did document white race as a risk factor for PTLD in a large cohort of children with renal transplants (35) . Conversely, Katz et al failed to identify an association between race and PTLD in a small case-control study of pediatric heart transplant recipients (36) . In multivariate models, Kobayashi et al found black race to be highly associated with shorter CAV-free survival in pediatric heart transplant recipients (37) .
Can racial differences in outcomes be explained by recipient and donor characteristics? Our large study cohort provided the opportunity to explore whether racial disparities could be explained by confounding variables. We observed several differences in baseline characteristics between patients of black and nonblack race. Black recipients were less likely to be infants at transplant and had significantly higher incidence of cardiomyopathy as the indication for transplantation. They were less likely to have commercial insurance and had higher incidence of donor-recipient race mismatch.
In our first multivariable models, we adjusted for demographic and clinical recipient and donor characteristics to determine whether race persisted as an independent risk factor for those posttransplant outcomes that we had previously identified to be associated with black race in the unadjusted models. We observed in these analyses that black race remains an independent risk factor for death, graft loss, severe RHC, late rejection, and late RHC. However, these variables appear to explain only a small proportion of the differences in outcome by race, and provide limited insight into mechanisms for these differences.
Do genetic differences in immune function explain racial differences in posttransplant outcomes?
In complex disorders, including therapeutic interventions such as transplantation, common genetic variations likely influence the occurrence, severity, and response to treatment of many clinical outcomes (37, 38) . We have previously investigated the influence of genetic polymorphisms on posttransplant outcomes within this SCCOR program (10, 11, 18, 39, 40) using a candidate gene approach. Among a panel of 20 genes, we have studied over 30 genotypes. The identification of novel associations or the confirmation of prior observations between common genetic variations and transplant outcomes was not the primary goal of the present study. Nevertheless, our extensive dataset is presented for reference (Table 6 ). Several genotypes were strongly associated (e.g. p < 0.001) with patient and graft survival and rejection outcomes in the univariate analyses, and these observations will require future validation in large cohorts of pediatric heart transplant recipients. They should also be explored for generalizability in other transplant organ types and age groups.
Among all the genotypes explored, variations in the gene encoding angiotensin-converting enzyme (ACE) had the strongest association with graft and patient survival in the multivariable model. ACE is an exopeptidase in the reninangiotensin-aldosterone system, which catalyzes the conversion of angiotensin I to the potent vasoconstrictor angiotensin II, while degrading the vasodilator bradykinin. The ACE deletion (D) allele is associated with higher plasma ACE levels as compared with the insertion (I) allele and has been closely linked with the development of CAV (41, 42) . Studies have found pediatric heart transplant recipients who inherit a D allele are more likely to experience graft dysfunction, RHC, and death after transplantation (10, 43) . Our findings are consistent with prior observations and are of particular relevance since ACE represents a well-established therapeutic target in cardiovascular disease. It remains possible that there could be other loci in high linkage disequilibrium that could be responsible. Of note, ACE genotype did not differ by race and, in general, there was no evidence in this cohort of interactions between race and genetic variants. However, we recognize that interaction tests were underpowered.
What are the mechanisms underlying differences in outcomes by race? A weakness of prior studies has been failure to integrate clinical, demographic, and genetic information from the same population into multivariable models within a single study design. Using our genetic database and the PHTS prospective clinical dataset, we have been able to investigate the contribution of both clinical and genetic data to key posttransplant outcomes that differ by race and have determined that these factors explain only up to 20% of the excess risk.
The observation of increased frequency of adverse late outcomes in black recipients as compared to other racial groups warrants further exploration. The underlying mechanisms behind these discrepancies are poorly understood. A uniform definition of race does not exist and the concept of race, in and of itself, is very complex. Its multifaceted nature, including genetic, cultural, and socioeconomic elements, adds further complexity, and renders the evaluation of racial influence on disease outcome challenging.
Race is known to be associated with SES, another variable that has been correlated with posttransplantation outcomes in the heart transplant population (7, 9) . Lower SES has been implicated as a predictor of poor recipient outcome (4, 8) . In our study, we used insurance status as a proxy for SES in the multivariable analysis due to an absence of information on household income and educational level in the PHTS database. Lower SES might be associated with poorer access to maintenance health care including immunosuppressive medications. While we did observe higher use of public insurance in black recipients, it should be noted that most children in the United States, in contrast to adults, have access to longterm immunosuppressive medications due to various safety net programs. We did observe differences in immunosuppressive regimens by race, but it is unclear to what extent these could explain the differences in clinical outcomes. The drug use variables were not significant in any of the clinical outcome models (i.e. they were not independently associated with the clinical outcomes) nor did the inclusion of these variables change the estimated effect of race on the clinical outcomes in any meaningful way. There was lower use of induction therapy in black recipients, which could potentially represent a transplant center effect, and not a race effect. Nonetheless, an early report from the PHTS suggested a survival benefit up to 3 years posttransplantation for children receiving induction with rabbit polyclonal antibody (44) . Two recent reports, using data from the United Network for Organ Sharing, show less late graft loss with induction, especially for patients with congenital heart disease or high panel reactive antibody (45) , and when antithymocyte globulin is used for induction compared to basiliximab (46) . No studies specifically address the interactions of race and induction therapy on very late graft outcomes in this population and this area requires further investigation.
Some have speculated that late adherence to medications may be poorer in certain patient populations (47) . This is certainly a hypothesis worth investigating, but was outside the scope of the present study. It would be purely speculative at this time to infer that black pediatric heart transplant recipients had lower adherence rates in our cohort.
Children of black race were also more likely to be older at the time of transplantation, and suffer from cardiomyopathy. Both variables should be associated with improved outcomes for black recipients, in the early hazard (perioperative) phase of posttransplant survival (48, 49) . Transplantation in infancy, however, does confer improved late outcomes (50), likely due to a greater degree of immune privilege (51) . This could contribute to some of the improved late outcomes in nonblack recipients, although we observed that the racial effect persisted after adjusting for age and other variables. There is no evidence in the pediatric heart literature to suggest that specific pretransplant diagnosis contributes to improved late outcomes and in the multivariable models, diagnosis was not independently associated with any outcomes.
Certain polymorphisms in genes involved in inflammation, tissue repair, immune response, and drug disposition have been determined to negatively impact posttransplantation outcomes (10, 18) and have been demonstrated by our group to be unequally distributed in terms of frequency among racial groups (13) . Based upon our past work, black recipients may have a genetic predisposition that renders a pro-inflammatory/low regulatory immunological environment and decreased immunosuppressive efficacy due to reduced drug exposure. However, the aim of the present study was to define the relative contributions of clinical, demographic, and select genetic variations on observed racial differences in outcomes, rather than to identify the impact of specific individual genetic variations on transplant outcomes (which has been the focus of our prior studies). Our current findings suggest that overall, observed genetic variations explain, at least in small part, some of the racial disparity in posttransplant outcomes.
Study Limitations
In this study, racial groups were not designated based on genetic analyses, but were parent-reported. Patients were enrolled in a cross-sectional manner and followed prospectively. Thus, recipients within the PHTS who died prior to commencement of the current study would not be included in the analysis. Medication adherence continues to pose a challenge in pediatric transplant recipients, particularly adolescents. However, the PHTS database lacks information regarding patient adherence and the study was, therefore, not designed to assess adherence. We have also not attempted to address the issue of preformed or de novo anti-HLA antibodies within this study. The PHTS database has no information on the donor specificity of alloantibodies and we believe that analysis based simply on pretransplant panel reactive antibodies would add little to the analysis. Information on development of de novo antibodies is not collected as part of PHTS nor this particular study. These issues are currently being addressed in appropriately designed prospective studies by the cardiac consortium of the Clinical Trials in Organ Transplantation in Children (National Institutes of Health/National Institute of Allergy and Infectious Diseases). There was nonuniformity in the selection of immunosuppressive regimens across transplant centers, and over time, and immunosuppressive regimen was also associated with race. Furthermore, racial distribution was not even across transplant centers. These complex interactions could only be partly explored as it was not possible to adjust for center along with all the other relevant demographic variables while maintaining stable estimates in the models. In addition, drug dose and plasma concentration data are not collected within the PHTS database. This directly limits our understanding of the potential role of pharmacogenetic factors in our study findings. Our choice of candidate genes for study of genetic influences was extensive but not comprehensive. Invariably, with large numbers of statistical tests, some associations may have occurred by chance, and these associations will require validation in large patient cohorts. It should also be noted that the candidate gene approach, as opposed to genomewide association studies or sequencing of entire genes, exomes, or genomes, precludes the possibility of discovering new genetic variants or pathways that might be important in determining patient outcomes after transplantation and which could further explain racial disparities. Such a genomewide approach is certainly desirable but would require too large a sample size to be feasible in our pediatric population.
Conclusions
There are several important observations from this study: (1) in a large population of pediatric heart recipients, we have identified racial differences in late posttransplant outcomes: death, graft loss, RHC requiring inotropes, late rejection, and late RHC; (2) black race remained an independent risk factor in multivariable models for all of these outcomes after adjusting for demographic, clinical, and genetic variables; (3) various genetic polymorphisms were identified as being associated with the clinical outcomes investigated in this study; and (4) genetic variation, demographic, and clinical variables explained only the minority of the effect of race on the outcomes.
The racial disparity in clinical outcomes following heart transplantation represents an important public health issue. Sustained emphasis should be placed on further investigating of the causal factors for these disparities and for strategies to minimize them.
